STUDY OF DRUG RSVIG-IV TO PROTECT CHILDREN WITH BRONCHOPULMONARY DYSPLASIA

药物 RSVIG-IV 保护支气管肺发育不良儿童的研究

• 批准号: 5221698
• 负责人: CYNTHIA BARRETT
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5221698
• 关键词: Pneumovirus vaccine; antiviral antibody; bronchopulmonary dysplasia; clinical research; communicable disease control; disease /disorder proneness /risk; drug screening /evaluation; human subject; human therapy evaluation; immunoglobulin G; infant human (0-1 year); intravenous administration; passive immunization; premature infant human; respiratory infections; respiratory syncytial virus

The objective of this study is to evaluate the safety and efficacy of intravenous RSV immunoglobulin infusions given monthly during the RSV season to reduce the rate of RSV hospitalizations in premature infants and infants with bronchopulmonary dysplasia.

本研究的目的是评价 RSV期间每月静脉输注RSV免疫球蛋白 减少早产儿RSV住院率的季节 和患有支气管肺发育不良的婴儿。